AAVnerGene Inc

07/09/2026

Another milestone for AAV gene therapy.

The FDA has cleared an IND for an National Center for Advancing Translational Sciences (NCATS) sponsored investigational AAV9/SUMF1 gene therapy for Multiple Sulfatase Deficiency(MSD), an ultra-rare and life-limiting pediatric lysosomal storage disorder with no approved disease-modifying treatment. The clearance paves the way for a first-in-human clinical trial.

This development highlights the continued potential of AAV9 vectors to address rare genetic diseases by delivering functional gene copies to target tissues.

Congratulations to the researchers, clinicians, and organizations involved in advancing this important program.

https://www.contemporarypediatrics.com/view/fda-clears-ind-investigational-sumf1-gene-therapy-multiple-sulfatase-deficiency

FDA cleared an IND for a NCATS-sponsored AAV9/SUMF1 gene therapy in multiple sulfatase deficiency, moving the ultra-rare disease toward its first-in-human trial.

07/02/2026

🚀 Another big win for AAV gene therapy!

Congratulations to Novartis on the European Commission approval of Itvisma®, an -based gene replacement therapy for a broader SMA patient population, including older children, teens, and adults.

This milestone further demonstrates the transformative potential of vectors in delivering one-time therapies that address disease at its genetic root.

This link will take you to a page that’s not on LinkedIn

06/24/2026

Key Insights into Custom AAV Packaging Inc.

Every gene, every construct, every project is different, and at AAVnerGene Inc., we believe your AAV solution should be too.

👉 What makes our approach different?
✅ and Vector Design
Customized strategies to maximize gene expression and fit your exact application, with confidentiality guaranteed.

✅ High-Quality AAV Packaging
Optimized workflows, consistent performance, and scalable solutions all 100% operations.

✅ Fast Turnaround Time
Only AAV packaging service TAT(shipping included) when all plasmids are ready.

✅ Gene-Specific Titration 🚫𝗡𝗼 𝗠𝗼𝗿𝗲 𝗜𝗧𝗥 𝗧𝗶𝘁𝗲𝗿𝘀
Go beyond generic measurements with accurate, biologically meaningful titers you can rely on for reproducible results.

💡 Whether you need a unique construct, optimized packaging, or dependable AAV supply, we build solutions around your research goals. Let’s create something tailored together.

06/09/2026

🚫 𝗡𝗼 𝗠𝗼𝗿𝗲 𝗜𝗧𝗥 𝗧𝗶𝘁𝗲𝗿𝘀
Let’s be honest:
ITR‑based AAV titers are outdated.
For years, the field has relied on ITR qPCR as a “standard.”
But in reality:
❌ Measures anything with ITR sequences, not functional vectors
❌ Includes fragmented genomes and incomplete particles
❌ Reports artificially inflated AAV titers

⚠️ The Problem We Don’t Discuss Enough
If you’re still using ITR titers:
👉 You don’t know your true dose
👉 You don’t know your functional AAV content
👉 You may be making decisions based on misleading data
In extreme cases,
reported titers can appear hundreds‑fold higher than meaningful vector content.

✅ 𝗔𝘁 𝗔𝗔𝗩𝗻𝗲𝗿𝗚𝗲𝗻𝗲: 𝗪𝗲 𝗗𝗼 𝗧𝗵𝗶𝗻𝗴𝘀 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁𝗹𝘆
We’ve moved beyond ITR titers.
Our AAV packaging service is built on:
🎯 Gene‑specific titer quantification
We measure:
✔️ Your gene of interest — not ITR artifacts
✔️ Biologically relevant vector content
✔️ What actually drives transduction and outcome

🚀 Where the Field Needs to Go
Stop relying on legacy convenience assays
Start demanding accuracy and functional relevance
Align analytics with real biological performance

🔥 No more inflated numbers.
No more false confidence.
No more ITR titers.

06/02/2026

Meet with our CTO, Dr. Qizhao Wang, at ASGCT Booth #741 to discuss next-generation AAV manufacturing solutions. At AAVnerGene, we not only provide the AAVone® single-plasmid AAV production system, but also offer the HEK293one producer cell line and PEIone transfection reagent to support efficient, ...

06/02/2026

🚀 News Release | AAVnerGene

Inc. is pleased to announce the launch of ®2.1, the next-generation evolution of our proprietary single-plasmid AAV production platform, designed to improve productivity, full-capsid yield, scalability, and cost efficiency in AAV gene therapy manufacturing.

®2.1 has achieved ~1e16 GC/L of cell culture and >70% full capsids at harvest, while demonstrating performance across multiple AAV serotypes and compatibility with HEK293-based cell lines and existing manufacturing workflows.

Manufacturing remains a critical constraint for AAV gene therapy. By reducing plasmid requirements, culture volume, purification burden, processing complexity, and potential manufacturing cost, ®2.1 is designed to help more AAV programs become clinically and commercially viable.

We welcome discussions with gene therapy developers, biopharma companies, and strategic partners looking to advance scalable AAV manufacturing.

🔗For more details, please read the full @ announcement: https://lnkd.in/ekSVxEge

03/17/2026

AAVnerGene‘s partner ’ Founder & CEO, Dr. Joseph Sinkule, sat down with Professor Tim Sandle, Ph.D., CBiol, FIScT of Digital Journal to discuss how cell and could transform the treatment of motor neuron and neurodegenerative diseases.

In the Q&A, Dr. Sinkule explores the science behind the gene, the company’s focus on neuroprotection and longevity, and progress across Klotho’s lead programs, including KLTO-101 for diseases and KLTO-202 for and other neuromuscular disorders.

https://www.digitaljournal.com/tech-science/qa-harnessing-cell-and-gene-therapy-to-treat-motor-neuron-diseases/article

03/17/2026

Ultragenyx reports positive Phase 3 data for DTX301 ( )

Ultragenyx announced positive Phase 3 results from the Enh3ance trial of DTX301, an AAV8‑based gene therapy for ornithine transcarbamylase (OTC) deficiency. The study met its primary endpoint, demonstrating a statistically significant reduction in 24‑hour plasma ammonia at 36 weeks, with effects observed early and maintained over time.

Importantly, patients were able to maintain ammonia control while reducing standard therapies, and the treatment showed a favorable safety profile following a single IV AAV dose.

This is a strong late‑stage validation for systemic AAV delivery, reinforcing the role of functional potency, durability, and manufacturing consistency in advancing AAV gene therapies toward commercialization.

Read the latest press releases from Ultragenyx to follow the latest developments.

03/11/2026

A new study just showcased one of the boldest uses of AAV in neurodegeneration to date: delivering ‑engineered astrocytes across the entire brain using systemic AAV‑PHP.eB.

Why this matters？
✅ AAV‑PHP.eB enabled noninvasive, CNS‑wide delivery of CAR constructs — no direct brain injection needed.
✅ A single AAV dose programmed astrocytes to seek and clear amyloid‑β, reducing plaque burden in vivo.

This work pushes beyond gene replacement into cell‑reprogramming therapy, emerging a major leap for Alzheimer’s and CNS disease strategies.

💥 AAV isn’t just a delivery vector — it’s becoming the engine behind the next generation of precision brain therapies.

https://www.science.org/doi/10.1126/science.ads3972